About Leucid Bio
Leucid Bio is a company based in London (United Kingdom) founded in 2014 by John Maher. Leucid Bio has raised $21.54 million across 3 funding rounds from investors including Epidarex Capital, 2Invest AG and Vulpes. The company has 10 employees. Leucid Bio offers products and services including Lateral CAR Platform, T4 Immunotherapy, LEU011, and Novel Manufacturing Platforms. Leucid Bio operates in a competitive market with competitors including Jazz Pharmaceuticals, Celgene, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter London, United Kingdom
- Employees 10
- Founders John Maher
- Stage Minicorn
- SectorsHealthcare
- Website leucid.com
- Social LinkedIn X
- Legal Name Leucid Bio Ltd
- Date of Incorporation 27 Nov, 2014
- Jurisdiction CAMBRIDGE, ENGLAND
- Total Equity Funding$21.54M (USD)
in 3 rounds
- Latest Funding Round$16.19M (USD), Series A
Jun 2021
- InvestorsEpidarex Capital
& 4 more
- Employee Count10
Products & Services of Leucid Bio
Leucid Bio offers a comprehensive portfolio of products and services, including Lateral CAR Platform, T4 Immunotherapy, LEU011, and Novel Manufacturing Platforms.
Redesigned CAR structure enhances T-cell potency for cancer treatment.
Autologous CAR T-cell product for head and neck cancer patients.
Targets NKG2D ligands in solid tumours and haematological malignancies.
Rapid, scalable method using blood draws for cell therapy.
Funding Insights of Leucid Bio
Leucid Bio has successfully raised a total of $21.54M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $16.19 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21.54M
- Total Rounds 3
- Last Round Series A — $16.19M
- First Round $2.92M
(Jul 2017)
- Investors Count 5
All 3 funding rounds of Leucid Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $16.19M | Series A | $44.36M | Epidarex Capital, Vulpes Investment Management | |
| Aug 2019 | $2.43M | Seed | $8.7M | – | – |
| Jul 2017 | $2.92M | Seed | $••••• | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Jun 2021 | $44.36M | •••••••• |
| Aug 2019 | $8.7M | •••••••• |
| Jul 2017 | $••••• | •••••••• |
Full valuation and stage history of Leucid Bio
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $44.36M (Jun 2021). 5 investors in total: 5 institutional.
Investors in Leucid Bio
Leucid Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Epidarex Capital, 2Invest AG and Vulpes.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | epidarex.com | - | |
Investments in biotechnology, life sciences, and IT are managed by 2Invest AG. | – | 2invest-ag.com | - | |
Early-stage tech and offline investments are managed across sectors. | – | vulpesinvest.com | Singapore, Singapore | |
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
Sovereign Wealth Fund of Government of Australia | – | futurefund.gov.au | Melbourne, Australia |
Investor details for Leucid Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Leucid Bio
16 people are tracked at Leucid Bio (8 in leadership, 8 in team); the tracked headcount is 10.
| Name | Role | Group |
|---|---|---|
John Maher | Co-Founder | Leadership |
Artin Moussavi | CEO | Leadership |
Belinda Carlsen | VP Clinical Operations | Leadership |
Filippo Petti | CEO | Leadership |
Arindam Mitra | Director,cmc | Leadership |
Caroline Malai Hull | Associate Director | Leadership |
Maya Glover | Associate Director | Leadership |
Fahima Kausar | Associate Director | Leadership |
Daniel Larcombe-Young | Senior Scientist | Team |
Nivetha R | CMC Specialist | Team |
Roisin Beehag | Senior Clinical Project Manager | Team |
Chris Davis | Senior Scientist | Team |
Kyvi Nguyen | CMC Specialist | Team |
Peter J. | Senior Scientist | Team |
Tara McIntosh-Sidonie | CMC Specialist | Team |
Victor del | Quality Assurance Manager | Team |
Complete people profiles for Leucid Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Leucid Bio
4 dated milestones of Leucid Bio across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Leucid Bio is founded.
- Funding First funding round of $2.9M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series A, of $16.2M.
Competitors of Leucid Bio
Leucid Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Celgene, C4 Therapeutics, Erasca and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| celgene.com | 1986 | Summit, United States | $45M | 4,891 | Therapies for cancer and inflammatory diseases are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Leucid Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Leucid Bio
Complete news archive for Leucid Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Leucid Bio
10 companies that operate in the same segment as Leucid Bio (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Leucid Bio
Leucid Bio was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Leucid Bio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Artin Moussavi is the current CEO of Leucid Bio.
Leucid Bio is a funded company, having raised a total of $21.54M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.92M, raised on Jul 2017.
Leucid Bio has 10 employees.
Developer of therapeutics for the treatment of cancers. The company has CAR T-cell therapies which reprogram patients immune cells to recognize and destroy the cancer cells. The drug candidates include LEU-001 and LEU-005 for solid tumors, LEU-004, and LEU-006 for hematological malignancies.
Leucid Bio's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Leucid Bio offers Lateral CAR Platform, T4 Immunotherapy, LEU011, and Novel Manufacturing Platforms.
Leucid Bio has 5 investors. Key investors include Epidarex Capital, 2Invest AG, Vulpes, Future Fund, and Sofinnova Partners.
The valuation of Leucid Bio is $44.36M as of Jun 2021.
Leucid Bio operates through Leucid Bio Ltd.